TENAX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
TENAX THERAPEUTICS, INC. (TENX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $13.27 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-31
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $13.27.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $5.93, a 0.17% decline from fiscal 2024.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.94.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.00.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $2.12.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 8 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.27 10-Q · filed 2026-07-31 | ||||
| 2026-03-31 | $13.27 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $5.93 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | $5.87 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $5.89 10-Q · filed 2025-08-13 | ||||
| 2024-12-31 | $5.94 10-K · filed 2026-03-10 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-25 | ||||
| 2016-12-31 | $2.12 10-K · filed 2017-03-16 | ||||
| 2015-12-31 | $3.25 10-K · filed 2017-03-16 | ||||
| 2015-04-30 | $4.82 10-K · filed 2017-03-16 | ||||
| 2014-04-30 | $5.64 10-K · filed 2017-03-16 | ||||
| 2013-04-30 | $32.60 10-KT · filed 2016-03-14 | ||||
| 2012-04-30 | $38.80 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |